New Drugs Health-System Pharmacists Should Know

JUNE 18, 2015
Allison Gilchrist, Associate Editor
In an acclaimed session at the American Society of Health-System Pharmacists’ 2015 Summer Meetings and Exposition in Denver, Tom Frank, PharmD, BCPS, of the Department of Pharmacy Practice at the University of Arkansas for Medical Sciences, walked health-system pharmacists through the new drugs for 2015 they can expect to handle.
Dr. Frank provided attendees with a detailed list of 22 new medications, describing the indications, pharmacology, adverse effects, dosing, and associated costs for each.
He spent a large portion of the session on new drugs targeting certain conditions, namely hepatitis C virus (HCV), diabetes, skin infections, and atrial fibrillation.
Hepatitis C
  • Sofosbuvir (Sovaldi) by Gilead
  • Ledipsavir and sofosbuvir (Harvoni) by Gilead
  • Ombitsavir, paritaprevir co-dosed with ritonavir, and dasabuvir (Viekira PAK) by AbbVie
All 3 of these HCV drugs are characterized by shorter treatment durations and improved efficacy and safety profiles. However, Dr. Frank said, the high costs associated with chronic HCV treatments should prompt pharmacists to reconsider their formula for determining the drugs’ worth.